Cargando…
Gut microbiota signatures and modulation in irritable bowel syndrome
Irritable bowel syndrome (IBS) affects approximately one tenth of the general population and is characterized by abdominal pain associated with abnormalities in bowel habits. Visceral hypersensitivity, abnormal intestinal motor function, mucosal immune activation, and increased intestinal permeabili...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688783/ https://www.ncbi.nlm.nih.gov/pubmed/38045643 http://dx.doi.org/10.20517/mrr.2021.12 |
_version_ | 1785152237377421312 |
---|---|
author | Marasco, Giovanni Cremon, Cesare Barbaro, Maria Raffaella Stanghellini, Vincenzo Barbara, Giovanni |
author_facet | Marasco, Giovanni Cremon, Cesare Barbaro, Maria Raffaella Stanghellini, Vincenzo Barbara, Giovanni |
author_sort | Marasco, Giovanni |
collection | PubMed |
description | Irritable bowel syndrome (IBS) affects approximately one tenth of the general population and is characterized by abdominal pain associated with abnormalities in bowel habits. Visceral hypersensitivity, abnormal intestinal motor function, mucosal immune activation, and increased intestinal permeability concur to its pathophysiology. Psychological factors can influence symptom perception at the central nervous system level. In addition, recent evidence suggests that dysbiosis may be a key pathophysiological factor in patients with IBS. Increasing understanding of the pathophysiological mechanisms translates into new and more effective therapeutic approaches. Indeed, in line with this evidence, IBS therapies nowadays include agents able to modulate gut microbiota function and composition, such as diet, prebiotics, probiotics, and antibiotics. In addition, in the last decade, an increasing interest in fecal microbiota transplantation has been paid. An in-depth understanding of the intestinal microenvironment through accurate faucal microbiota and metabolite analysis may provide valuable insights into the pathophysiology of IBS, finally shaping new tailored IBS therapies. |
format | Online Article Text |
id | pubmed-10688783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106887832023-12-02 Gut microbiota signatures and modulation in irritable bowel syndrome Marasco, Giovanni Cremon, Cesare Barbaro, Maria Raffaella Stanghellini, Vincenzo Barbara, Giovanni Microbiome Res Rep Review Irritable bowel syndrome (IBS) affects approximately one tenth of the general population and is characterized by abdominal pain associated with abnormalities in bowel habits. Visceral hypersensitivity, abnormal intestinal motor function, mucosal immune activation, and increased intestinal permeability concur to its pathophysiology. Psychological factors can influence symptom perception at the central nervous system level. In addition, recent evidence suggests that dysbiosis may be a key pathophysiological factor in patients with IBS. Increasing understanding of the pathophysiological mechanisms translates into new and more effective therapeutic approaches. Indeed, in line with this evidence, IBS therapies nowadays include agents able to modulate gut microbiota function and composition, such as diet, prebiotics, probiotics, and antibiotics. In addition, in the last decade, an increasing interest in fecal microbiota transplantation has been paid. An in-depth understanding of the intestinal microenvironment through accurate faucal microbiota and metabolite analysis may provide valuable insights into the pathophysiology of IBS, finally shaping new tailored IBS therapies. OAE Publishing Inc. 2022-03-05 /pmc/articles/PMC10688783/ /pubmed/38045643 http://dx.doi.org/10.20517/mrr.2021.12 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Marasco, Giovanni Cremon, Cesare Barbaro, Maria Raffaella Stanghellini, Vincenzo Barbara, Giovanni Gut microbiota signatures and modulation in irritable bowel syndrome |
title | Gut microbiota signatures and modulation in irritable bowel syndrome |
title_full | Gut microbiota signatures and modulation in irritable bowel syndrome |
title_fullStr | Gut microbiota signatures and modulation in irritable bowel syndrome |
title_full_unstemmed | Gut microbiota signatures and modulation in irritable bowel syndrome |
title_short | Gut microbiota signatures and modulation in irritable bowel syndrome |
title_sort | gut microbiota signatures and modulation in irritable bowel syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688783/ https://www.ncbi.nlm.nih.gov/pubmed/38045643 http://dx.doi.org/10.20517/mrr.2021.12 |
work_keys_str_mv | AT marascogiovanni gutmicrobiotasignaturesandmodulationinirritablebowelsyndrome AT cremoncesare gutmicrobiotasignaturesandmodulationinirritablebowelsyndrome AT barbaromariaraffaella gutmicrobiotasignaturesandmodulationinirritablebowelsyndrome AT stanghellinivincenzo gutmicrobiotasignaturesandmodulationinirritablebowelsyndrome AT barbaragiovanni gutmicrobiotasignaturesandmodulationinirritablebowelsyndrome |